AR007059A1 - Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto - Google Patents

Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto

Info

Publication number
AR007059A1
AR007059A1 ARP970101925A ARP970101925A AR007059A1 AR 007059 A1 AR007059 A1 AR 007059A1 AR P970101925 A ARP970101925 A AR P970101925A AR P970101925 A ARP970101925 A AR P970101925A AR 007059 A1 AR007059 A1 AR 007059A1
Authority
AR
Argentina
Prior art keywords
interferon
contact
medicines
preparation
compositions via
Prior art date
Application number
ARP970101925A
Other languages
English (en)
Original Assignee
Pharma Pacific Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Pacific Pty Ltd filed Critical Pharma Pacific Pty Ltd
Publication of AR007059A1 publication Critical patent/AR007059A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)

Abstract

El uso de interferón para preparar un medicamento o una composición que contiene una cantidad terapéuticamente efectiva de un interferón adaptada parael contacto oromucosal para tratar una enfermedad neoplásica en mamíferos . La cantidad deinte rferón administrado es menor que la cantidad que induce unarespuesta patológica cuando es administrada parenteralmente.
ARP970101925A 1996-05-09 1997-05-08 Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto AR007059A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPN9765A AUPN976596A0 (en) 1996-05-09 1996-05-09 Stimulation of host defence mechanisms

Publications (1)

Publication Number Publication Date
AR007059A1 true AR007059A1 (es) 1999-10-13

Family

ID=3794078

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP970101924A AR007058A1 (es) 1996-05-09 1997-05-08 Uso de interferon en medicamentos y composiciones para contacto oromucosal
ARP970101925A AR007059A1 (es) 1996-05-09 1997-05-08 Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP970101924A AR007058A1 (es) 1996-05-09 1997-05-08 Uso de interferon en medicamentos y composiciones para contacto oromucosal

Country Status (17)

Country Link
EP (2) EP0956040B1 (es)
JP (2) JP3806444B2 (es)
KR (2) KR100399499B1 (es)
CN (1) CN1154508C (es)
AR (2) AR007058A1 (es)
AT (2) ATE316793T1 (es)
AU (3) AUPN976596A0 (es)
BR (2) BR9709066A (es)
CA (2) CA2253908A1 (es)
DE (2) DE69735204T2 (es)
ES (2) ES2260790T3 (es)
ID (2) ID16885A (es)
IL (2) IL126972A0 (es)
NZ (2) NZ332688A (es)
TW (1) TW528599B (es)
WO (2) WO1997041883A1 (es)
ZA (1) ZA973988B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299871B1 (en) * 1998-07-24 2001-10-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Orally-administrable therapeutic and/or prophylactic agent for HTLV-1-related diseases
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
WO2000071148A2 (en) * 1999-05-26 2000-11-30 The Brigham And Women's Hospital, Inc. Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin
US20040258663A1 (en) * 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
DE602005002673T2 (de) 2004-04-29 2008-07-24 F. Hoffmann-La Roche Ag Nukleotidsequenzvariation im Gen NS5A als Marker
DE102007014752A1 (de) 2007-03-28 2008-10-02 Dusek, Niels, Dr. Verwendung von humanidentischem oder humanaequivalentem rekombinantem Interleukin-2 (heqlL-2) als Therapeutikum in der Human- und Veterinärmedizin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982000588A1 (en) * 1980-08-22 1982-03-04 Illinois Univ Delivery of biologically active components of heterologous species interferon isolates
US5286748A (en) * 1981-01-05 1994-02-15 Eby Iii George A General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity
US4820515A (en) * 1982-12-13 1989-04-11 Texas A&M University System Method of using interferon in low dosage to regulate appetite and efficiency of food utilization
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
JP2704546B2 (ja) * 1989-04-04 1998-01-26 光利 太良 Ａｔｌｌ治療用吸入剤
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5215741A (en) * 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
MX9102512A (es) * 1990-12-14 1992-06-01 Schering Corp Administracion oral de interferon alfa en el tratamiento de enfermedades del pulmon.
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
ATE316792T1 (de) * 1996-05-09 2006-02-15 Pharma Pacific Pty Ltd Stimulierung wirtseigener abwehrmechanismen gegen krebs

Also Published As

Publication number Publication date
ID16885A (id) 1997-11-20
JP2000504027A (ja) 2000-04-04
CN1154508C (zh) 2004-06-23
AU2710997A (en) 1997-11-26
AU2399297A (en) 1997-11-26
BR9709223A (pt) 2000-12-12
JP3806444B2 (ja) 2006-08-09
DE69735204D1 (de) 2006-04-13
TW528599B (en) 2003-04-21
ES2260794T3 (es) 2006-11-01
DE69735201D1 (de) 2006-04-13
ZA973988B (en) 1998-11-09
ATE316791T1 (de) 2006-02-15
JP3806446B2 (ja) 2006-08-09
KR100399499B1 (ko) 2003-12-18
ATE316793T1 (de) 2006-02-15
EP0956040A1 (en) 1999-11-17
AU729514B2 (en) 2001-02-01
CN1218409A (zh) 1999-06-02
EP0898478A4 (en) 1999-05-26
IL126970A0 (en) 1999-09-22
AR007058A1 (es) 1999-10-13
ES2260790T3 (es) 2006-11-01
KR20000010880A (ko) 2000-02-25
EP0956040B1 (en) 2006-02-01
DE69735204T2 (de) 2006-09-21
EP0898478A1 (en) 1999-03-03
BR9709066A (pt) 2000-01-04
JP2000504026A (ja) 2000-04-04
KR20000010882A (ko) 2000-02-25
EP0898478B1 (en) 2006-02-01
AU724190B2 (en) 2000-09-14
NZ332690A (en) 2000-07-28
AUPN976596A0 (en) 1996-05-30
CA2253908A1 (en) 1997-11-13
WO1997041883A1 (en) 1997-11-13
WO1997041886A1 (en) 1997-11-13
EP0956040A4 (es) 1999-11-17
IL126972A0 (en) 1999-09-22
ID16886A (id) 1997-11-20
KR100399501B1 (ko) 2003-12-18
CA2253902A1 (en) 1997-11-13
NZ332688A (en) 2000-07-28
DE69735201T2 (de) 2006-09-21

Similar Documents

Publication Publication Date Title
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
EP0552256A4 (es)
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
DK0600079T3 (da) Oral 1alpha-hydroxyprævitamin D
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
BRPI0410260A (pt) composição conjugada para medicamento
BR0107869A (pt) Composições farmacêuticas eletrogiradas
ES2055845T3 (es) Composicion farmaceutica para el tratamiento de la osteoporosis.
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
BR9913945A (pt) Composição farmacêutica para o tratamento de distúrbios agudos por meio de administração sublingual, e, processo para o tratamento de distúrbios agudos
HK1030157A1 (en) Use of consensus interferon and compositions comprising consensus interferon.
DK0470117T3 (da) Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner
BR9916114A (pt) Uso de apomorfina na fabricação de um medicamento para tratamento de disfunção erétil orgânica masculina
PT1001802E (pt) Preparacao farmaceutica combinada compreendendo a hormona da paratiroide e um inibidor de reabsorcao ossea
AU7284098A (en) Method for preventing gastritis using amylin or amylin agonists
AR007059A1 (es) Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
KR910009267A (ko) 우울증의 치료방법
BR9106272A (pt) Composicoes farmaceuticas contendo ipriflavona,processo para sua preparacao e uso terapeutico relativo
ES2181915T3 (es) Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.
KR940701249A (ko) 진통제
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
ES2086536T3 (es) Uso de ketorolaco para el tratamiento de la enfermedad periodontal.
FI945446A (fi) Kotiinin käyttö tupakan vieroitusoireyhtymän lievittämiseksi
ES2101311T3 (es) Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer.